13.54
price down icon2.48%   -0.37
 
loading
Cvrx Inc stock is traded at $13.54, with a volume of 166.31K. It is down -2.48% in the last 24 hours and up +42.94% over the past month. CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$13.91
Open:
$13.95
24h Volume:
166.31K
Relative Volume:
0.53
Market Cap:
$339.21M
Revenue:
$47.26M
Net Income/Loss:
$-58.48M
P/E Ratio:
-6.4476
EPS:
-2.1
Net Cash Flow:
$-40.45M
1W Performance:
-14.31%
1M Performance:
+42.94%
6M Performance:
+63.63%
1Y Performance:
-23.36%
1-Day Range:
Value
$13.39
$14.19
1-Week Range:
Value
$13.39
$15.91
52-Week Range:
Value
$6.40
$33.13

Cvrx Inc Stock (CVRX) Company Profile

Name
Name
Cvrx Inc
Name
Phone
(763) 416-2850
Name
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Name
Employee
200
Name
Twitter
Name
Next Earnings Date
2024-10-29
Name
Latest SEC Filings
Name
CVRX's Discussions on Twitter

Compare CVRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
CVRX 13.56 339.21M 47.26M -58.48M -40.45M -2.10
ABT 117.52 202.64B 41.22B 5.77B 6.49B 2.94
SYK 392.22 148.70B 21.97B 3.59B 3.21B 6.74
BSX 90.67 133.82B 15.91B 1.79B 1.89B 0.82
MDT 87.84 112.92B 32.58B 3.93B 5.15B 2.71
EW 70.14 40.88B 6.60B 4.16B 490.10M 2.34

Cvrx Inc Stock (CVRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-10-24 Initiated Cantor Fitzgerald Overweight
Jul-11-24 Reiterated Lake Street Buy
May-01-24 Resumed Craig Hallum Buy
May-01-24 Downgrade JP Morgan Overweight → Neutral
May-01-24 Downgrade William Blair Outperform → Mkt Perform
Jan-31-23 Initiated Lake Street Buy
Jul-18-22 Initiated Craig Hallum Buy
Jul-26-21 Initiated Canaccord Genuity Buy
Jul-26-21 Initiated Piper Sandler Overweight
Jul-26-21 Initiated William Blair Outperform
View All

Cvrx Inc Stock (CVRX) Latest News

pulisher
Nov 17, 2024

CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Nov 17, 2024
pulisher
Nov 13, 2024

CVRx’s Barostim Gains New CPT Codes - MPO-mag

Nov 13, 2024
pulisher
Nov 11, 2024

(CVRX) Long Term Investment Analysis - Stock Traders Daily

Nov 11, 2024
pulisher
Nov 07, 2024

International Assets Investment Management LLC Makes New Investment in CVRx, Inc. (NASDAQ:CVRX) - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

CVRx: Impressive Top-Line Growth Seems Priced In - Seeking Alpha

Nov 06, 2024
pulisher
Nov 05, 2024

Cantor Fitzgerald Initiates Coverage of CVRx (CVRX) with Overweight Recommendation - MSN

Nov 05, 2024
pulisher
Nov 04, 2024

CVRx (NASDAQ:CVRX) Stock Price Expected to Rise, Craig Hallum Analyst Says - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

CVRx earns Medicare win for Barostim procedure - Mass Device

Nov 04, 2024
pulisher
Nov 04, 2024

CVRx gains CMS payment classification for Barostim - Investing.com

Nov 04, 2024
pulisher
Nov 04, 2024

CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025 - GlobeNewswire

Nov 04, 2024
pulisher
Nov 04, 2024

CVRx, Inc. (NASDAQ:CVRX) Position Decreased by Emerald Advisers LLC - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

CVRx, Inc. (NASDAQ:CVRX) Q3 2024 Earnings Call Transcript - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

FY2024 EPS Estimates for CVRx Lowered by Cantor Fitzgerald - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report - Simply Wall St

Nov 01, 2024
pulisher
Nov 01, 2024

CVRx, Inc. (NASDAQ:CVRX) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 01, 2024
pulisher
Oct 31, 2024

How the (CVRX) price action is used to our Advantage - Stock Traders Daily

Oct 31, 2024
pulisher
Oct 30, 2024

Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Earnings call: CVRx reports robust Q3 growth, eyes future reimbursement wins - Investing.com India

Oct 30, 2024
pulisher
Oct 30, 2024

CVRx (NASDAQ:CVRX) Given New $15.00 Price Target at Lake Street Capital - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

CVRx (NASDAQ:CVRX) Given "Overweight" Rating at Piper Sandler - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

CVRx Reports Strong Revenue Growth in Q3 2024 - TipRanks

Oct 30, 2024
pulisher
Oct 30, 2024

CVRx earnings missed by $0.10, revenue topped estimates - Investing.com Canada

Oct 30, 2024
pulisher
Oct 30, 2024

CVRx: Q3 Earnings Snapshot - The Advocate

Oct 30, 2024
pulisher
Oct 29, 2024

CVRx Reports Third Quarter 2024 Financial and Operating Results - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

CVRx Inc Q3 2024 Earnings: Revenue Hits $13.4M, EPS at -$0.57, S - GuruFocus.com

Oct 29, 2024
pulisher
Oct 29, 2024

CVRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 29, 2024
pulisher
Oct 26, 2024

CVRx (CVRX) Price Target Increased by 10.54% to 33.15 - MSN

Oct 26, 2024
pulisher
Oct 24, 2024

CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 24, 2024

CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles - Investing.com India

Oct 24, 2024
pulisher
Oct 23, 2024

CVRx (NASDAQ:CVRX) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

Oct 23, 2024
pulisher
Oct 23, 2024

Cantor Fitzgerald stays positive on CVRx, reaffirms $14 stock PT after survey - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 23, 2024
pulisher
Oct 22, 2024

CVRx (CVRX) Set to Announce Earnings on Tuesday - MarketBeat

Oct 22, 2024
pulisher
Oct 21, 2024

CVRx, Inc. Shares Surge Following Key Heart Failure Treatment Approval - Stocks Telegraph

Oct 21, 2024
pulisher
Oct 21, 2024

CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock? - Yahoo Finance

Oct 21, 2024
pulisher
Oct 21, 2024

Canaccord maintains Buy rating on CVRx stock - Investing.com

Oct 21, 2024
pulisher
Oct 21, 2024

Canaccord maintains Buy rating on CVRx stock By Investing.com - Investing.com UK

Oct 21, 2024
pulisher
Oct 21, 2024

CVRx announces new CPT Category I codes for Barostim heart failure therapy - Yahoo Finance

Oct 21, 2024
pulisher
Oct 19, 2024

AMA approves new codes for heart failure therapy By Investing.com - Investing.com Australia

Oct 19, 2024
pulisher
Oct 19, 2024

CVRx announces new CPT® Category I codes for Barostim - The Manila Times

Oct 19, 2024
pulisher
Oct 18, 2024

AMA approves new codes for heart failure therapy - Investing.com

Oct 18, 2024

Cvrx Inc Stock (CVRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_devices STE
$217.96
price down icon 0.99%
medical_devices ZBH
$113.33
price up icon 0.74%
medical_devices PHG
$25.98
price up icon 0.56%
$77.45
price up icon 2.05%
$82.35
price up icon 0.78%
medical_devices EW
$70.12
price up icon 3.64%
Cap:     |  Volume (24h):